Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Sensitivity of the Hypothalamic GnRH Pulse Generator to Estradiol and Progesterone Inhibition

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Girls ages 8 to 14~* Tanner 1-3 pubertal stage~* Pre-menarchal~* Normal screening labs~Exclusion Criteria:~* Abnormal screening labs~* Congenital adrenal hyperplasia~* Hyperandrogenism (e.g., hirsutism, elevated free testosterone level)~* Hemoglobin \<12 mg/dL or hematocrit \< 36% (Subjects will be offered the opportunity to take iron supplementation for 60 days if their hematocrit is slightly low (33-36%) (suggestive of iron deficiency anemia) and will then return for retesting of their hemoglobin/hematocrit.)~* Weight \< 31 kg~* History of peanut allergy, deep venous thrombosis, breast cancer, endometrial cancer, or cervical cancer~* On hormonal medications (including oral contraceptive pills) or on medications known to affect the reproductive axis within 3 months of the study~* Pregnant or breast feeding~* Participation in a research study within the past 30 days that involved taking a study drug.~* Participation in a research study that involved taking up to or greater than 473 ml's of blood within the past 60 days.~* Cigarette smoking~* History of surgery that required bedrest within the past 30 days~* Family history of hypercoagulability or unexplained thromboembolic disease (not in setting of bedrest, surgery, or malignancy)~* In order to ensure an adequate number of younger girls, no more than 4 enrolled subjects will be Tanner stage 3

- Gender: FEMALE
- Minimum Age: 8 Years
- Maximum Age: 14 Years
- Healthy Volunteers: t

Study Arms:
- Progesterone, estrace (Type: EXPERIMENTAL): oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr to achieve mean plasma concentrations over the range of 2-8 ng/ml for seven days~oral estrace, 0.5-1 mg once a day for seven days

Based on this trial design, predict the completion outcome and termination type (if applicable).